

Navamedic ASA: Appointment of CFO

Oslo, 8 December 2025: Navamedic ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") is pleased to announce that the Company has appointed Nils Ole Krekling Chief Financial Officer (CFO) of Navamedic ASA, effective 1 January 2026.

Mr. Krekling joins Navamedic from Kongsberg Gruppen ASA, where he currently serves as Group VP Corporate Development and Head of M&A.

"With extensive experience from both finance and strategy roles, Mr. Krekling brings valuable expertise that will strengthen our financial leadership and support our strategic ambitions," says Kathrine Gamborg Andreassen, CEO of Navamedic.

"I am pleased to join Navamedic as CFO. Navamedic is a well-established organization with bold ambitions, and I look forward to joining the team and contributing to the Company's continued financial performance and strategic development," says Nils Ole Krekling.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com.

About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, addiction, metabolism and antibiotics, to empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit www.Navamedic.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.